A Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for fluasterone in the treatment of the manifestations of Cushing syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Fluasterone (Primary)
Indications Cushing syndrome; Metabolic syndrome; Non-alcoholic fatty liver disease
Focus Adverse reactions; Therapeutic Use

11 Dec 2020 New trial record
02 Dec 2020 According to a SteroTherapeutics media release, Dr. Constantine Stratakis will be leading this study.
02 Dec 2020 According to a SteroTherapeutics media release, Under the terms of the CRADA, SteroTherapeutics will provide the study drug and placebo to enable the NICHD to conduct the clinical study. The study will be conducted under the rubric of company's Investigational New Drug authorization with the goal of advancing fluasterone to a pivotal Phase 3 study and marketing approval by 2023-24.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com